Treatment and prognosis of hepatocellular carcinoma: a population based study in France

Frédéric Borie1, Anne-Marie Bouvier, Astrid Herrero

  • 1Registre des Tumeurs de l'Hérault, Centre de Recherche, Montpellier Cedex, France. fborie@yahoo.com

Insights

Hepatocellular carcinoma (HCC) management and prognosis in France show poor outcomes, with most patients receiving limited palliative care. Enhanced prevention strategies are crucial for improving survival rates in HCC patients.

Area of Science:

  • Hepatobiliary Medicine
  • Oncology
  • Epidemiology

Background:

  • Limited population-based data exist on hepatocellular carcinoma (HCC) management and prognosis.
  • Understanding HCC in a French population is essential for public health initiatives.

Purpose of the Study:

  • To report on the management and prognosis of hepatocellular carcinoma (HCC) in a French population.
  • To compare clinical presentation, treatment, and survival rates between HCC with and without cirrhosis.

Main Methods:

  • Analysis of 1,007 registered HCC cases from 1997-1998 in nine French departments.
  • Comparison of clinical presentation and treatment in patients with and without cirrhosis.
  • Determination of prognosis using crude and relative survival rates, including multivariate analysis.

Main Results:

  • HCC was associated with cirrhosis in 79% of cases and without cirrhosis in 15%.
  • Symptoms were the primary discovery mode (63-70%); diagnosis was histologically verified in 50% (cirrhosis) and 80% (no cirrhosis).
  • Five-year survival rates were low overall (6-9%), with slightly better outcomes for non-cirrhotic cases (28-29%) versus cirrhotic cases (34-39% for specific treatments, 6% overall). Liver transplant offered 60% 5-year survival in 24 cases.

Conclusions:

  • Hepatocellular carcinoma (HCC), with or without cirrhosis, demonstrates a poor prognosis.
  • Current treatments are largely palliative and offer limited efficacy.
  • Significant advancements in primary and secondary prevention are urgently needed.
Abstract

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...